This wiki has undergone a migration to Confluence found Here
<meta name="googlebot" content="noindex">

Difference between revisions of "BiologicallyDerivedProduct FHIR Resource Proposal"

From HL7Wiki
Jump to navigation Jump to search
(initial edit)
Line 38: Line 38:
 
<!-- Additional work groups that may have an interest in contributing to, or reviewing  the content of the resource (optional) -->
 
<!-- Additional work groups that may have an interest in contributing to, or reviewing  the content of the resource (optional) -->
 
* Orders and Observations
 
* Orders and Observations
 +
* Pharmacy
  
 
==FHIR Resource Development Project Insight ID==
 
==FHIR Resource Development Project Insight ID==

Revision as of 21:34, 9 September 2017



BiologicallyDerivedProduct

Owning committee name

Patient Care

Committee Approval Date:

Please enter the date that the committee approved this Resource proposal

Contributing or Reviewing Work Groups

  • Orders and Observations
  • Pharmacy

FHIR Resource Development Project Insight ID

Scope of coverage

Substances taken from one biological entity (person, animal, etc) or modifications of such substances, intended to be injected, transplanted or grafted to another (possibly the same) biological entity. This includes but is not limited to:

  • blood (whole, extracted cells, plasma, etc)
  • hematopoietic stem cells (bone marrow, peripheral blood, or cord blood extraction)
  • organs
  • tissues (porcine valves, skin, bovine cardiac tissue, etc.)
  • manipulated cells (e.g. CAR T-cells)

RIM scope

Resource appropriateness

Expected implementations

Content sources

Example Scenarios

Resource Relationships

Timelines

gForge Users

When Resource Proposal Is Complete

When you have completed your proposal, please send an email to FMGcontact@HL7.org

FMG Notes